Johnson Controls International Plc
$97.97B- Market cap
- $88.43B
- Debt
- +$9.92B
- Cash
- −$379.00M
Capital structure 90% equity / 10% debt · EV / Revenue 4.15x · EV / EBITDA 22.80x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: JCI stock price vs IOVA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at IOVA's multiple
Needs IOVA P/E.
Implied fair value · at JCI's multiple
Needs EPS (TTM) is negative, JCI P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: JCI FY 2025 (ended Sep 30, 2025) · IOVA FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 90% equity / 10% debt · EV / Revenue 4.15x · EV / EBITDA 22.80x
Capital structure 100% equity / 0% debt · EV / Revenue 13.99x
JCI carries the larger enterprise value at $97.97B against $3.69B; JCI trades on the lower EV / Revenue multiple (4.15x vs 13.99x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
JOHNSON CONTROLS INTERNATIONAL PLC · implied price per share
Bear
$15.00
Base
$20.10
Bull
$27.78
IOVANCE BIOTHERAPEUTICS, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.77x
0.00x
Net debt / EBITDA
Leverage against operating earnings
2.22x
0.83x
Cash and equivalents
Liquid reserves on the balance sheet
$379.00M
$296.98M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
CARRIER GLOBAL Corp
JCI vs CARR
AAON, INC.
JCI vs AAON
COMFORT SYSTEMS USA INC
JCI vs FIX
Trane Technologies plc
JCI vs TT
LENNOX INTERNATIONAL INC
JCI vs LII
Allegion plc
JCI vs ALLE
BioNTech SE
JCI vs BNTX
Moderna, Inc.
JCI vs MRNA
GILEAD SCIENCES, INC.
JCI vs GILD
Legend Biotech Corp
JCI vs LEGN
$9.92B
$1.00M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.